Herceptin First-Line Use In Breast Cancer Grows With 90% HER2 Testing
First-line use of Genentech's Herceptin (trastuzumab) is increasing with the growing number of breast cancer patients who are being tested for overexpression of the HER2 protein.
First-line use of Genentech's Herceptin (trastuzumab) is increasing with the growing number of breast cancer patients who are being tested for overexpression of the HER2 protein.